UBS Group’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-225,147
| Closed | -$7.54M | – | 10985 |
|
|
2026
Q1 | $7.54M | Buy |
225,147
+55,641
| +33% | +$2.18M | ﹤0.01% | 3640 |
|
|
2025
Q4 | $7.85M | Buy |
169,506
+11,198
| +7% | +$614K | ﹤0.01% | 3553 |
|
|
2025
Q3 | $10.7M | Buy |
158,308
+52,312
| +49% | +$3.88M | ﹤0.01% | 3221 |
|
|
2025
Q2 | $8.88M | Buy |
105,996
+48,519
| +84% | +$3.63M | ﹤0.01% | 3198 |
|
|
2025
Q1 | $4.11M | Buy |
57,477
+7,322
| +15% | +$357K | ﹤0.01% | 3993 |
|
|
2024
Q4 | $2.25M | Buy |
50,155
+5,490
| +12% | +$284K | ﹤0.01% | 4609 |
|
|
2024
Q3 | $2.26M | Buy |
44,665
+10,715
| +32% | +$513K | ﹤0.01% | 3871 |
|
|
2024
Q2 | $1.39M | Sell |
33,950
-19,855
| -37% | -$841K | ﹤0.01% | 4116 |
|
|
2024
Q1 | $2.3M | Buy |
53,805
+36,017
| +202% | +$1.63M | ﹤0.01% | 3804 |
|
|
2023
Q4 | $716K | Buy |
+17,788
| New | +$506K | ﹤0.01% | 4788 |
|
|
2023
Q3 | – | Sell |
-15
| Closed | -$64 | – | 9923 |
|
|
2023
Q2 | $64 | Buy |
+15
| New | +$65 | ﹤0.01% | 8572 |
|
|
2022
Q3 | – | Sell |
-3,646
| Closed | -$10K | – | 10869 |
|
|
2022
Q2 | $10K | Buy |
+3,646
| New | +$10.1K | ﹤0.01% | 7994 |
|
|
2022
Q1 | – | Sell |
-2,014
| Closed | -$12K | – | 10842 |
|
|
2021
Q4 | $12K | Buy |
2,014
+927
| +85% | +$9.73K | ﹤0.01% | 8577 |
|
|
2021
Q3 | $15K | Buy |
1,087
+1,023
| +1,598% | +$14.3K | ﹤0.01% | 7517 |
|
|
2021
Q2 | $1K | Sell |
64
-2,401
| -97% | -$40.6K | ﹤0.01% | 9188 |
|
|
2021
Q1 | $47K | Buy |
2,465
+1,798
| +270% | +$58K | ﹤0.01% | 6630 |
|
|
2020
Q4 | $19K | Sell |
667
-839
| -56% | -$24.2K | ﹤0.01% | 6992 |
|
|
2020
Q3 | $57K | Buy |
1,506
+263
| +21% | +$7.69K | ﹤0.01% | 5551 |
|
|
2020
Q2 | $41K | Buy |
1,243
+891
| +253% | +$38.6K | ﹤0.01% | 6038 |
|
|
2020
Q1 | $13K | Buy |
352
+233
| +196% | +$9.91K | ﹤0.01% | 6780 |
|
|
2019
Q4 | $5K | Sell |
119
-197
| -62% | -$5.04K | ﹤0.01% | 7595 |
|
|
2019
Q3 | $7K | Buy |
316
+22
| +7% | +$702 | ﹤0.01% | 7351 |
|
|
2019
Q2 | $12K | Sell |
294
-92
| -24% | -$3.18K | ﹤0.01% | 6956 |
|
|
2019
Q1 | $12K | Buy |
386
+250
| +184% | +$6.64K | ﹤0.01% | 6693 |
|
|
2018
Q4 | $3K | Buy |
+136
| New | +$3.97K | ﹤0.01% | 7731 |
|
|
2018
Q3 | – | Sell |
-265
| Closed | -$9K | – | 8241 |
|
|
2018
Q2 | $9K | Buy |
265
+107
| +68% | +$3.14K | ﹤0.01% | 7202 |
|
|
2018
Q1 | $4K | Buy |
+158
| New | +$4.31K | ﹤0.01% | 7346 |
|
|
2017
Q4 | – | Sell |
-223
| Closed | -$9K | – | 8071 |
|
|
2017
Q3 | $9K | Buy |
223
+165
| +284% | +$6.51K | ﹤0.01% | 6958 |
|
|
2017
Q2 | $2K | Buy |
+58
| New | +$2.69K | ﹤0.01% | 7397 |
|
|
2017
Q1 | – | Sell |
-75
| Closed | -$5K | – | 7929 |
|
|
2016
Q4 | $5K | Buy |
75
+72
| +2,400% | +$4.99K | ﹤0.01% | 7250 |
|
|
2016
Q3 | $0 | Buy |
+3
| New | +$228 | ﹤0.01% | 7905 |
|
|
2016
Q2 | – | Sell |
-32
| Closed | -$3K | – | 7945 |
|
|
2016
Q1 | $3K | Sell |
32
-228
| -88% | -$22.3K | ﹤0.01% | 7206 |
|
|
2015
Q4 | $36K | Buy |
+260
| New | +$38.1K | ﹤0.01% | 6148 |
|
|
2015
Q3 | – | Sell |
-16
| Closed | -$3K | – | 8608 |
|
|
2015
Q2 | $3K | Buy |
+16
| New | +$6.15K | ﹤0.01% | 8085 |
|
|
2015
Q1 | – | Sell |
-27
| Closed | -$3K | – | 9326 |
|
|
2014
Q4 | $3K | Buy |
+27
| New | +$5.56K | ﹤0.01% | 9269 |
|
UBS Group's SLNO Position: Q2 2026 in Review
UBS Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 225,147 shares — an estimated $7.54M sold.
UBS Group first reported a position in SLNO in Q4 2014 and held it in 35 quarters. The position peaked at $10.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- UBS Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 225,147 Soleno Therapeutics shares in Q2 2026, an estimated $7.54M.
- UBS Group first reported a position in Soleno Therapeutics in Q4 2014 and held it in 35 quarters.
- UBS Group's Soleno Therapeutics position peaked at $10.7M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.